Predicting resistance to synthetic lethal therapies in cancer
Background Synthetic lethality (SL) occurs when an alteration in one gene renders cells vulnerable to inhibition of another, offering a strategy for targeted cancer therapy. PARP inhibitors represent the first clinically approved synthetic lethal therapy, and numerous additional candidates are now in clinical trials. Unfortunately, resistance to these therapies is common and impairs their overall…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
